Inhaled corticosteroids and long acting β2-agonists in asthma and chronic obstructive pulmonary disease (COPD)

Apply

Inhaled corticosteroids and long acting β2-agonists in asthma and chronic obstructive pulmonary disease (COPD)

Journal Title: Przewodnik Lekarza - Year 2005, Vol 78, Issue 6

Abstract

Agonists of β2 receptors are the most potent bronchial dilators. Available long-acting β2-agonists are widely used in the treatment of both bronchial asthma and COPD. However, administration of these drugs alone is rather disadvantageous because of the risk of tachyphylaxis. Other group of medicines used in the bronchial asthma and COPD are inhaled glucorticosteroids. They are the first choice drugs in asthma therapy and their effectiveness is well documented. If, however, they are ineffective is the administered dose, its increase does not bring about desired effect. In such a situation addition of the long-acting β2-agonists accelerate stabilization of the disease course. Recently, several papers were published, positively assessing the use of such a combined therapy in COPD. An effect of both components are considered additive and not simply summed up.

Authors and Affiliations

Anna Doboszyńska

Keywords

wziewne glikokortykosteroidy leki długo działające z grupy agonistów receptorów β2-adrenergicznych astma POChP

EP ID EP123540
DOI -
Views 94
Downloads 0